Valuation hits a ten-year low! Barclays initiates coverage on 26 US medical technology stocks, with Stryker (SYK.US) among its top picks
Barclays analyst Christopher Pasquale on Tuesday initiated coverage on 26 US-listed medtech companies for the first time, and included Stryker (SYK.US) and Abbott (ABT.US) on the recommended list of large-cap medtech stocks.
According to Zhihu Finance APP, Barclays analyst Christopher Pasquale on Tuesday initiated coverage of 26 U.S.-listed medical technology companies for the first time, placing Stryker (SYK.US) and Abbott (ABT.US) on the recommended list of large-cap medical technology stocks. The bank noted that the recent underperformance of the medical technology sector provides investors with an opportunity to buy high-quality companies at attractive valuations.
Before Pasquale voiced his optimistic outlook, the sector benchmark iShares U.S. Medical Devices ETF (IHI.US) had fallen nearly 19% over the past five years, while the S&P 500 Index rose nearly 77% over the same period.
In his report, he wrote: “After several years of relative underperformance due to slowing revenue growth, medical technology stocks are now trading at their lowest valuations in a decade, and at the deepest discount to the S&P 500 Index since the peak of the tech bubble.”
He described the current sell-off as an overreaction, partly due to multiple company-specific headwinds over the past year, “making the industry’s return to average growth rates appear as if fundamentals have deteriorated more significantly.”
Pasquale expects that a potential stabilization in large-cap medical technology companies’ revenues next year could serve as a catalyst to boost market sentiment and valuation multiples. “While we believe investors should remain cautious until the outlook becomes clearer, we are convinced that the current market environment offers quite attractive investment opportunities,” he added.
Which stocks are worth buying? Stryker and Edwards Lifesciences top the overweight list
Barclays named Stryker and Edwards Lifesciences (EW.US) as their top large-cap picks, with target prices of $375 and $110, respectively. Other large-caps rated as “Overweight” include Abbott, with a target price of $120; GE HealthCare Technologies (GEHC.US), with a target price of $85; and Intuitive Surgical (ISRG.US), with a target price of $485.
For small and mid-cap stocks, Barclays singled out Beta Bionics (BBNX.US), Dexcom (DXCM.US), and LivaNova (LIVN.US) as their top picks, with target prices of $30, $115, and $105, respectively. Other small and mid-cap medical technology stocks rated as “Overweight” include Axogen (AXGN.US), with a target price of $55; Bausch + Lomb (BLCO.US), with a target price of $24; Procept BioRobotics (PRCT.US), with a target price of $30; and TransMedics (TMDX.US), with a target price of $120.
Which stocks require caution? Medtronic and Boston Scientific rated “Neutral”; Baxter and Becton Dickinson downgraded
Companies rated as “Neutral” include: Alcon (ALC.US), target price $70; Averitas Technologies (AVR.US), target price $10; Boston Scientific (BSX.US), target price $48; Humacyte (HUMA.US), target price $0.50; Insulet (PODD.US), target price $150; Medtronic (MDT.US), target price $95; Minimed (MMED.US), target price $22; Senseonics (SENS.US), target price $10; Tandem Diabetes (TNDM.US), target price $18; Cooper Companies (COO.US), target price $60; Zimmer Biomet (ZBH.US), target price $100.
Companies rated as “Underweight” include: Baxter International (BAX.US), target price $20; Becton Dickinson (BDX.US), target price $165; Inspire Medical (INSP.US), target price $65.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Jefferies bullish on US cruise sector; Royal Caribbean rises on rating upgrade
October 8th - ** Shares of U.S. cruise company Royal Caribbean (RCL.N) rose 1.2% in pre-market trading to $285.85 ** Jefferies upgraded RCL from "Hold" to "Buy" and raised its price target from $305 to $330 ** The firm also raised its price target for Lindblad Expeditions Holdings (LIND.O) from $29 to $32; LIND shares were flat pre-market ** "We are optimistic about the long-term prospects of the cruise industry as its share in the global vacation market continues to grow," said Jefferies ** The firm noted significant upside in the sector given strong revenue performance ** "We also believe that in the 2027 fiscal year, cruise stocks will be very attractive value investments under various macroeconomic scenarios, with land-based travel products providing additional growth momentum for earnings," Jefferies added ** As of the previous trading day’s close, RCL shares had risen 1.2% and LIND is up 143% year-to-date
Deutsche Bank: Changes in Investor Positions and Capital Flows
New Generation of Crypto Miners Released by ASICID
BUZZ - Levi Strauss shares drop due to weak sales in the US and Europe
On October 8, Levi Strauss (LEVI.N) shares fell 1.3% in pre-market trading to $19.25 after the company reported lower-than-expected sales in the U.S. and Europe. BTIG commented: “This quarter, the European direct-to-consumer (DTC) business was hit by unusually warm weather, but as temperatures return to normal, foot traffic and sales trends have improved, maintaining a positive outlook in early Q4.” The brokerage also noted that the company remains strong in wholesale, e-commerce, and market share in jeans, but its “back-to-school” marketing campaign did not meet expectations. Benefiting from tariff refunds on Wednesday, the company raised its annual profit forecast and is betting on strong demand for its premium jeans and sweaters during the holiday season. Sixteen analysts have an average “buy” rating; the median price target is $27, according to LSEG. The stock has risen 6% year-to-date as of the previous close.
Crypto prices
More
